NCT07141186View on ClinicalTrials.gov

QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2030

Conditions
Cervical CancerCervical Cancer MetastaticCervical Cancer RecurrentCervical AdenocarcinomaCervical Cancer Squamous Cell
Interventions
DRUG

QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

Enrolled patients will receive intravenous infusion of QL1706 once every 3 weeks at a dose of 5.0 mg/kg until disease progression, death, intolerable treatment toxicity, or withdrawal from the clinical trial for any reason.

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER